조현병 환자의 인지결핍에 대한 약물학적 접근에 대한 고찰
A Review of Pharmacological Strategy for Cognitive Deficits in Schizophrenia
0
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Cognitive deficit is frequently observed in patients with schizophrenia. It is significantly associated with functional outcome. In the past 20 years, due to significant advances on the concept of schizophrenia, cognitive deficit has been accepted as a core feature. In the DSM-5, cognitive deficit does not introduce diagnostic criteria of schizophrenia, but did one dimension of diagnosis of psychosis. Existing schizophrenia drugs are effective in treatment of positive symptoms of schizophrenia, but lack of effectiveness on improving cognitive function. Led by NIMH (National Institute of Mental Health), the MATRICS (Measurement and Treatment Research to Improve Cognition in Schizophrenia) meeting was conducted in order to achieve consensus on measuring tools and neuropharmacological targets for clinical trials for development of new drugs for improvement of cognitive function in schizophrenia. At the MATRICS consensus meeting, glutamatergic modulators and nicotinic and muscarinic agonists are expected to be promising, but should be proven by a double-blind placebo-controlled multicenter study for patients.
Abstract
Cognitive deficit is frequently observed in patients with schizophrenia. It is significantly associated with functional outcome. In the past 20 years, due to significant advances on the concept of schizophrenia, cognitive deficit has been accepted as a core feature. In the DSM-5, cognitive deficit does not introduce diagnostic criteria of schizophrenia, but did one dimension of diagnosis of psychosis. Existing schizophrenia drugs are effective in treatment of positive symptoms of schizophrenia, but lack of effectiveness on improving cognitive function. Led by NIMH (National Institute of Mental Health), the MATRICS (Measurement and Treatment Research to Improve Cognition in Schizophrenia) meeting was conducted in order to achieve consensus on measuring tools and neuropharmacological targets for clinical trials for development of new drugs for improvement of cognitive function in schizophrenia. At the MATRICS consensus meeting, glutamatergic modulators and nicotinic and muscarinic agonists are expected to be promising, but should be proven by a double-blind placebo-controlled multicenter study for patients.
참고문헌 (26)
- Green MF, "Stimulating the development of drug treatments to im-prove cognition in schizophrenia", Annu Rev Clin Psychol, 3, pp.159~180 (2007)
- Green MF, "Cognition in schizophrenia: Past, present, and future", Schizophrenia Research: Cognition, 1, pp.1~9 (2014)
- Tonmoy S, "Cognition in schizophrenia: Impairments, Im-portance and Treatment Strategies", pp.3~335 (2000), Oxford university press
- Opler LA, "Pharmacotherapy of cognitive deficits in schizophrenia", CNS Spectr, 19, pp.142~156 (2014)
- Kahn RS, "Schizophrenia is a cognitive illness: Time for a change in focus", JAMA Psychiatry, 70, pp.1107~1112 (2013)
- Green MF, "Commentary on “cognition in schizophrenia”", Eur Neu-ropsychopharmacol, 23, pp.786~787 (2013)
- Kirkpatrick B, "The NIMH-MATRICS consensus statement on negative symptoms", Schizophr Bull, 32, pp.214~219 (2006)
- Keefe RS, "Clinical trials of potential cognitive-enhancing drugs in schizophrenia: What have we learned so far?", Schizophr Bull, 39, pp.417~435 (2013)
- Goldberg TE, "Comment on “cognition in schizophrenia:Summary nice consultation meeting 2012”", Eur Neuropsychophar-macol, 23, pp.788~789 (2013)
- Green MF, "Approaching a consensus cognitive battery for clinical tri-als in schizophrenia: the NIMH-MATRICS conference to select cog-nitive domains and test criteria", Biol Psychiatry, 56, pp.301~307 (2004)
- 이승환, "정신분열병의 인지기능 향상을 위한 새로운 약물개발 - MATRICS의 소개 -", 대한정신약물학회지, 16(4), pp.272~278 (2005), 대한정신약물학회
- Nuechterlein KH, "The MATRICS consensus cognitive battery, part 1:Test selection, reliability, and validity", Am J Psychiatry, 165, pp.203~213 (2008)
- Nutt D, "Cognition in schizophrenia: Summary nice consultation meet-ing 2012", Eur Neuropsychopharmacol, 23, pp.769~778 (2013)
- Pinkham AE, "The social cognition psychometric evaluation study: Results of the expert survey and RAND panel", Schizophr Bull, 40, pp.813~823 (2014)
- Green MF, "Adapting social neuroscience mea-sures for schizophrenia clinical trials, part 1: Ferrying paradigms across perilous waters", Schizophr Bull, 39, pp.1192~1200 (2013)
- Tamminga CA, "The neurobiology of cognition in schizophrenia", J Clin Psychiatry, 67, pp.9~13 (2006)
- Javitt DC, "Glutamatergic theories of schizophrenia", Isr J Psychia-try Relat Sci, 47, pp.4~16 (2010)
- Lin CH, "Glutamate signaling in the pathophys-iology and therapy of schizophrenia", Pharmacol Biochem Behav, 100, pp.665~677 (2012)
- Yasuhara A, "Metabotropic glutamate receptors: Potential drug targets for psychiatric disorders", Open Med Chem J, 4, pp.20~36 (2010)
- Paz RD, "Glutamatergic dysfunction in schizophrenia: From basic neuroscience to clinical psychophar-macology", Eur Neuropsychopharmacol, 18, pp.773~786 (2008)
- 이정구, "Adjunctive Memantine Therapy for Cognitive Impairment in Chronic Schizophrenia: A Placebo-Controlled Pilot Study", PSYCHIATRY INVESTIGATION, 9(2), pp.166~173 (2012), 대한신경정신의학회
- Ochoa EL, "Cognitive deficits in schizophrenia: Focus on neuronal nicotinic acetylcholine receptors and smoking", Cell Mol Neurobiol, 27, pp.609~639 (2007)
- Arneric SP, "Neuronal nicotinic receptors:A perspective on two decades of drug discovery research", Biochem Pharmacol, 74, pp.1092~1101 (2007)
- Shim JC, "Ad-junctive varenicline treatment with antipsychotic medications for cognitive impairments in people with schizophrenia: A random-ized double-blind placebo-controlled trial", Neuropsychopharmacology, 37, pp.660~668 (2012)
- Lee SW, "A 12-week, double-blind, pla-cebo-controlled trial of galantamine adjunctive treatment to con-ventional antipsychotics for the cognitive impairments in chronic schizophrenia", Int Clin Psychopharmacol, 22, pp.63~68 (2007)
- Lee BJ, "A 12-week, double-blind, placebo-con-trolled trial of donepezil as an adjunct to haloperidol for treating cog-nitive impairments in patients with chronic schizophrenia", J Psychopharmacol, 21, pp.421~427 (2007)